Burlington, MA, United States of America

Kian Huat Lim

This inventor holds 4 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 5 EPO patents. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2016-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kian Huat Lim. Retrieved from https://idiyas.com/inventor/kian-huat-lim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0


 

Average Co-Inventor Count = 14.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016-2023

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Work of Inventor Kian Huat Lim in Cancer Research

Introduction:

Inventor Kian Huat Lim, based in Burlington, MA, has made significant contributions to the field of cancer research through his groundbreaking work in splice variants associated with neomorphic SF3B1 mutants.

Latest Patents:

With a portfolio of 4 patents, Lim's latest inventions focus on splice variants linked to neomorphic SF3B1 mutations. These patents encompass methods for detecting splice variants, diagnosing cancer, evaluating SF3B1 modulators, and treating cancer associated with SF3B1 mutations.

Career Highlights:

Kian Huat Lim is a valued member of the team at Eisai R&D Management Co., Ltd., a renowned pharmaceutical company known for its dedication to innovation in healthcare. His impactful research has positioned him as a key figure in the field of cancer genetics.

Collaborations:

Working alongside accomplished colleagues such as Silvia Buonamici and Lihua Yu, Lim has further enriched his research endeavors by engaging in collaborative projects that aim to push the boundaries of cancer treatment and understanding.

Conclusion:

In conclusion, Kian Huat Lim's pioneering work in cancer genetics, particularly focusing on splice variants associated with SF3B1 mutations, underscores his commitment to advancing medical research and delivering novel solutions for the diagnosis and treatment of cancer. His patents stand as a testament to his dedication and expertise in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…